FLGT - Can Fulgent Genetics Stock Rebound?
Can a diagnostics company that makes most of its money from coronavirus tests keep growing in a post-pandemic environment? Fulgent Genetics (NASDAQ: FLGT) shares are still far below their peak in February, despite reporting record revenue in the fourth quarter.
Could this stock deliver market-beating gains over the long run, or are its new shareholders setting themselves up for heartbreak once the COVID-19 vaccine supply catches up with demand? To find out where the company is headed, let's start with a quick look at its recent accomplishments.
Image source: Getty Images.
For further details see:
Can Fulgent Genetics Stock Rebound?